Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most undervalued NASDAQ stocks to buy now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported on September 17 that its experimental medicine garetosmab has met the primary endpoint in a phase 3 trial for adults with fibrodysplasia ossificans progressiva, a rare genetic condition in which muscles, tendons, and ligaments gradually convert into bone. According to the OPTIMA trial, at 56 weeks, both garetosmab dosages decreased new bone lesion ...

In this article, we will be taking a look at the Conservative Stock Portfolio: 11 Best Stocks to Buy Now.The equity market outlook has always been positive whenever the US Federal Reserve cuts rates in an accelerating economy. That has been the case as stocks have raced to record highs, defying seasonal weakness in September amid mounting concerns about macroeconomic indicators. Likewise, strategists at Bank of America believe the run in big tech stocks has further room to go despite two years of substantia ...

Fireblocks is a globally recognized leader in the digital assets space, facilitating the secure transfer of more than $10 trillion to date SARASOTA, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, announced that it has begun implementing its strategic agreement with Fireblocks, an enterprise platform for secure digital asset custody, settlement, trading operations, and s ...

Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second quarter 2025 investor letter for the "Baird Chautauqua International and Global Growth Fund". A copy of the letter can be downloaded here. Global equity markets experienced a significant shift during the quarter, moving from notable losses to reaching new highs. Markets fell following the President's announcement of unexpectedly severe tariffs, which raised recession fears. After a bri ...

CANADA - 2025/06/03: In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesMoonLake Immunotherapeutics (NASDAQ: MLTX), a biopharmaceutical firm in the clinical stage, experienced substantial fluctuations last week. The stock climbed 10% on Friday, September 26, as investors expected favorable outcomes from Phase 3 trials of son ...

Usman Azam, M.D., is appointed President and Chief Executive Officer of Cue Biopharma, effective September 29, 2025Daniel Passeri, Chief Executive Officer of Cue Biopharma, transitions to Strategic Advisor to provide ongoing support to the Company Cue Biopharma prioritizes autoimmune disease for next stage of growth with focus on advancing first-in-class tolerogenic biologic CUE-401 into the clinic BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceu ...

– Rademikibart demonstrated rapid and significant improvement in lung function and asthma control in patients, with greatest improvements observed in those with elevated baseline levels of key type 2 inflammatory markers – – Significant reduction in annualized exacerbations observed in patients with one or more elevated type 2 inflammatory markers at baseline – – Data supports ongoing Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies i ...

CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is th ...

Larimar Therapeutics (NasdaqGM:LRMR) Update / Briefing September 29, 2025 08:00 AM ET Company ParticipantsAlexandra Folias - Managing Director - United StatesCarole Ben-Maimon - President, CEO & DirectorJoori Park - VP - Equity ResearchJon Wolleben - Managing DirectorConference Call ParticipantsYatin Suneja - Senior MD & Biotechnology AnalystSamantha Semenkow - VP - SMid Biotech Equity Research AnalystJoon Lee - MD & Senior Biotech AnalystMyles Minter - Research Analyst - HealthcareCory Jubinville - MD & Re ...

ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has completed the Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of ...